Description

The global viscosupplementation market is poised to grow by US$ 2,567.4 million during 2022-2028, progressing at a CAGR of 8.4% during the forecast period, according to data and analytics company StrategyHelix.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for viscosupplementation. The global viscosupplementation market is segmented on the basis of product, application, end user, and region. By product, the global viscosupplementation market has been segmented into product, five-injection, single-injection, three-injection. The three-injection segment was the largest contributor to the global viscosupplementation market in 2021. Based upon application, the global viscosupplementation market is categorized into hip osteoarthritis, knee osteoarthritis, others. According to the research, the knee osteoarthritis segment had the largest share in the global viscosupplementation market. On the basis of end user, the global viscosupplementation market has been segmented into hospitals, ambulatory surgical centers (ASCs). Geographically, the global viscosupplementation market is segmented into Asia Pacific, Europe, North America, MEA (Middle East and Africa), Latin America. Globally, North America made up the largest share of the viscosupplementation market.

The global viscosupplementation market is highly competitive. The report also includes the profiles of leading companies such as Anika Therapeutics Inc., Bioventus LLC, Chugai Pharmaceutical Co. Ltd., Ferring B.V., Fidia Farmaceutici S.p.A., Lifecore Biomedical LLC, Sanofi S.A., Seikagaku Corp., Zimmer Biomet Holdings Inc. Competitive landscape gives a description of the competitive nature of the global viscosupplementation market and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the viscosupplementation market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Product: product, five-injection, single-injection, three-injection
Application: hip osteoarthritis, knee osteoarthritis, others
End user: hospitals, ambulatory surgical centers (ASCs)
Region: Asia Pacific, Europe, North America, MEA (Middle East and Africa), Latin America
Years considered: this report covers the period 2018 to 2028
Company mentioned: Anika Therapeutics Inc., Bioventus LLC, Chugai Pharmaceutical Co. Ltd., Ferring B.V., Fidia Farmaceutici S.p.A., Lifecore Biomedical LLC, Sanofi S.A., Seikagaku Corp., Zimmer Biomet Holdings Inc

Key Benefits for Stakeholders

– Get a comprehensive picture of the global viscosupplementation market
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Viscosupplementation market overview
Part 3. Market breakdown by product
– Product
– Five-injection
– Single-injection
– Three-injection
Part 4. Market breakdown by application
– Hip osteoarthritis
– Knee osteoarthritis
– Others
Part 5. Market breakdown by end user
– Hospitals
– Ambulatory surgical centers (ASCs)
Part 6. Market breakdown by region
– Asia Pacific
– Europe
– North America
– MEA (Middle East and Africa)
– Latin America
Part 7. Key companies
– Anika Therapeutics Inc.
– Bioventus LLC
– Chugai Pharmaceutical Co., Ltd.
– Ferring B.V.
– Fidia Farmaceutici S.p.A.
– Lifecore Biomedical LLC
– Sanofi S.A.
– Seikagaku Corp.
– Zimmer Biomet Holdings Inc
About StrategyHelix
Disclaimer